8FJA image
Entry Detail
PDB ID:
8FJA
EMDB ID:
Keywords:
Title:
CryoEM structure of HLA-A2 MAGEA4 (230-239) in complex with REGN6972 Fab
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-12-19
Release Date:
2023-12-20
Method Details:
Experimental Method:
Resolution:
3.00 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:MHC class I antigen
Chain IDs:C (auth: A)
Chain Length:277
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:D (auth: B)
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Melanoma-associated antigen 4 peptide
Chain IDs:E (auth: C)
Chain Length:10
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:REGN6972 Fab light chain
Chain IDs:A (auth: D)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:REGN6972 Fab heavy chain
Chain IDs:B (auth: E)
Chain Length:236
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Monoclonal antibody therapies have transformed the lives of patients across a diverse range of diseases. However, antibodies can usually only access extracellular proteins, including the extracellular portions of membrane proteins that are expressed on the cell surface. In contrast, T cell receptors (TCRs) survey the entire cellular proteome when processed and presented as peptides in association with human leukocyte antigen (pHLA complexes). Antibodies that mimic TCRs by recognizing pHLA complexes have the potential to extend the reach of antibodies to this larger pool of targets and provide increased binding affinity and specificity. A major challenge in developing TCR mimetic (TCRm) antibodies is the limited sequence differences between the target pHLA complex relative to the large global repertoire of pHLA complexes. Here, we provide a comprehensive strategy for generating fully human TCRm antibodies across multiple HLA alleles, beginning with pHLA target discovery and validation and culminating in the engineering of TCRm-based chimeric antigen receptor T cells with potent antitumor activity. By incorporating mass spectrometry, bioinformatic predictions, HLA-humanized mice, antibody screening, and cryo-electron microscopy, we have established a pipeline to identify additional pHLA complex-specific antibodies with therapeutic potential.

Legend

Protein

Chemical

Disease

Primary Citation of related structures